(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of -43.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Nurix Therapeutics's revenue in 2026 is $701,936,000.On average, 16 Wall Street analysts forecast NRIX's revenue for 2026 to be $80,442,823,044, with the lowest NRIX revenue forecast at $74,195,918,680, and the highest NRIX revenue forecast at $90,072,101,650. On average, 16 Wall Street analysts forecast NRIX's revenue for 2027 to be $10,530,808,071, with the lowest NRIX revenue forecast at $2,548,142,662, and the highest NRIX revenue forecast at $26,796,794,378.
In 2028, NRIX is forecast to generate $18,876,182,863 in revenue, with the lowest revenue forecast at $4,282,592,709 and the highest revenue forecast at $35,197,012,576.